Navigation Links
Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance
Date:2/12/2008

Reconciliation of Projected GAAP Basic Income per Common Share

to Basic Adjusted Income Per Common Share Guidance

(Unaudited)

Three Months Twelve Months

Ended Ended

March 31, 2008 December 31, 2008

Projected GAAP basic income per common

share $0.74 - $0.84 $4.04 - $4.14

Amortization of current intangibles $0.42 - $0.42 $1.68 - $1.68

Tax effect of pre-tax adjustments at

the applicable tax rates $(0.16)- $(0.16) $(0.62)- $(0.62)

Basic adjusted income per common share

guidance $1.00 - $1.10 $5.10 - $5.20

The company's guidance is being issued based on certain assumptions

including:

-- Entrance into the market of an additional generic version of ACTIQ by

mid-2008;

-- Approval of TREANDA and mid-2008 launch;

-- Reduction of interest income by $20 million resulting from payment of

the settlement with the U.S. Attorney's Office;

-- Adjusted effective tax rate of approximately 36 to 37 percent; and

-- Weighted average number of common shares outstanding of 67.5 million

shares for the three months ended March 31, 2008 and for the twelve

months ended December 31, 2008, respectively.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 2Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 3Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 4Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 5PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting 2PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting 3PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting 4CareEvolution and SCHIEx Named Interoperability Finalists for 2008 Microsoft Healthcare Users Group (MS-HUG) Healthcare Innovation Awards 2CareEvolution and SCHIEx Named Interoperability Finalists for 2008 Microsoft Healthcare Users Group (MS-HUG) Healthcare Innovation Awards 3